Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J on gainsharing

This article was originally published in The Gray Sheet

Executive Summary

CFO Robert Darretta tells investors during April 19 earnings call that the strategy by which some hospitals curb the cost of devices purchased - allowing doctors to share in the savings - is "something [the firm is] monitoring and, I am sure, we will have conversations about it in the future" (1"The Gray Sheet" April 11, 2005, p. 14). He added: "I am not sure about how [regulators] will feel about endorsing it [or] what length of time gains might be shared and among whom and how. Those things will have a significant impact on people's receptivity to the concept"...

You may also be interested in...

Ortho Firms Feel DoJ Probe Price As Stocks Fall In Q1; Will Zimmer Diversify?

The federal government's mounting scrutiny of orthopedic industry pricing practices for hip and knee replacement implants could convince Zimmer to more aggressively seek a presence in the artificial disc arena

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts